PharmAthene (PIP) Develops Anthrax Vaccine; Presenting Data at Upcoming International Conference
PharmAthene Inc. is a biodefense company focused on developing medical countermeasures against biological and chemical weapons. The company today issued an update on its Protective Antigen (rPA) anthrax vaccine development program, noting that it recently demonstrated the vaccine as structurally stable at various temperatures. Non-clinical data results show improved immunogenicity of the lyophilized vaccine formulation when compared to the liquid formulation. The results will be presented at the upcoming 2010 International Conference on Emerging Infectious Diseases, July 11-14 in Atlanta, Georgia. Eric I. Richman, president and interim CEO, said the company is working with strategic partners to seek out advancements…